公开(公告)号：US20240360153A1

公开(公告)日：2024-10-31

申请号：US18628171

申请日：2024-04-05

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： David Glass ,  Joseph P. Vacca ,  Tea Shavlakadze ,  Chester A. Metcalf, III ,  William Olson

IPC: C07D498/18 ,  A61K31/439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/497 ,  A61K39/395

CPC classification number: C07D498/18 ,  A61K31/439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/497 ,  A61K39/3955

Abstract: Compounds and pharmaceutical compositions for use in the treatment of a disorder or disease mediated by the mTOR pathway through more selective binding to FKBP12 of the group of FK506 binding proteins (FKBPs) are disclosed. With an unusual pharmacokinetic profile and an enhanced pharmacodynamic selectivity among target FKBPs, those compounds are useful for the treatment of age- or aging-related diseases, diabetes, cancers, as well as inflammation-associated disorders.

公开(公告)号：US20240358704A1

公开(公告)日：2024-10-31

申请号：US18627727

申请日：2024-04-05

Applicant: Hoffmann-La Roche Inc.

Inventor： Nicole HELLBACH ,  Heidemarie KLETZL ,  Friedrich METZGER ,  Renata SICILIANI SCALCO

IPC: A61K31/519 ,  A61K9/00 ,  A61K9/08 ,  A61K39/00 ,  A61K39/395 ,  A61P21/00

CPC classification number: A61K31/519 ,  A61K9/0053 ,  A61K9/0095 ,  A61K9/08 ,  A61K39/3955 ,  A61P21/00 ,  A61K2039/545

Abstract: The invention relates to 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one, also known as risdiplam, for use in the treatment of spinal muscular atrophy (SMA) with GYM329, its pharmaceutical composition to be used in the treatment of SMA, its methods of treatment thereof.

公开(公告)号：US20240358645A1

公开(公告)日：2024-10-31

申请号：US18652504

申请日：2024-05-01

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Yeon-Sun HONG ,  Yoo Soo YANG ,  In-San KIM

IPC: A61K9/48 ,  A61K31/337 ,  A61K31/407 ,  A61K31/704 ,  A61K38/47 ,  A61K39/395 ,  A61K41/00 ,  A61K45/06 ,  A61N5/10 ,  A61P35/00

CPC classification number: A61K9/48 ,  A61K31/337 ,  A61K31/407 ,  A61K31/704 ,  A61K38/47 ,  A61K39/3955 ,  A61K41/0057 ,  A61K45/06 ,  A61P35/00 ,  C12Y302/01035 ,  A61N5/10 ,  A61N2005/1098

Abstract: The present invention relates to a recombinant exosome containing hyaluronidase and a use thereof, and more particularly to a recombinant exosome that presents hyaluronidase on its surface and use thereof as an anticancer agent.

公开(公告)号：US12129294B2

公开(公告)日：2024-10-29

申请号：US18105316

申请日：2023-02-03

Applicant: AbbVie Inc.

Inventor： Gregg Timony ,  Sheila Gujrathi ,  Robert Peach ,  Allan Olson

IPC: C07K16/24 ,  A61K31/436 ,  A61K31/519 ,  A61K31/58 ,  A61K38/13 ,  A61K39/395 ,  A61K45/06 ,  A61P1/00 ,  A61P37/06

CPC classification number: C07K16/244 ,  A61K31/436 ,  A61K31/519 ,  A61K31/58 ,  A61K38/13 ,  A61K39/3955 ,  A61K45/06 ,  A61P1/00 ,  A61P37/06 ,  C07K2317/56

Abstract: The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an interleukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.

公开(公告)号：US20240350498A1

公开(公告)日：2024-10-24

申请号：US18750971

申请日：2024-06-21

Applicant: CARDIFF ONCOLOGY, INC.

Inventor： Maya Ridinger ,  Mark Erlander

IPC: A61K31/519 ,  A61K31/4745 ,  A61K31/513 ,  A61K39/395 ,  A61P35/04

CPC classification number: A61K31/519 ,  A61K31/4745 ,  A61K31/513 ,  A61K39/3955 ,  A61P35/04

Abstract: Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administrating a treatment comprising inhibiting angiogenesis and a PLK1 inhibitor (for example, onvansertib) to the subject that has not received prior anti-angiogenic treatment, in a manner sufficient to reduce or inhibit progression of the metastatic cancer.

公开(公告)号：US12122817B2

公开(公告)日：2024-10-22

申请号：US17184248

申请日：2021-02-24

Applicant: Serpentide Inc.

Inventor： Yang Wei

IPC: A61K38/26 ,  A61K39/395 ,  A61K45/06 ,  A61P3/10 ,  C07K14/605 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K14/605 ,  A61K38/26 ,  A61K39/3955 ,  A61K45/06 ,  A61P3/10 ,  C07K16/28 ,  C07K16/2869 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2319/30 ,  C07K2319/35 ,  C07K2319/50

Abstract: Modified glucagon-like peptide (GLP1) fusion proteins with modified GLP1 polypeptides and related methods of use are described. Aspects of the disclosure further relate to fusion proteins that are GLP1 receptor agonists with a modified GLP1 fused to a stabilizing domain such as an extra cellular domain or antibody. Fusion proteins with modified GLP1 that are useful for treating or ameliorating a symptom or indication of a blood sugar disorder such as obesity and diabetes are also provided.

公开(公告)号：US20240344102A1

公开(公告)日：2024-10-17

申请号：US18431564

申请日：2024-02-02

Applicant: Merus N.V.

Inventor： Cornelis Adriaan DE KRUIF ,  Linda Johanna Aleida Hendriks ,  Ton Logtenberg

IPC: C12P21/00 ,  A61K39/395 ,  A61K39/40 ,  C07K16/12 ,  C07K16/18 ,  C07K16/26 ,  C07K16/28 ,  C07K16/36 ,  C07K16/46 ,  A61K39/00

CPC classification number: C12P21/005 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/40 ,  C07K16/12 ,  C07K16/1278 ,  C07K16/1282 ,  C07K16/18 ,  C07K16/26 ,  C07K16/28 ,  C07K16/2809 ,  C07K16/283 ,  C07K16/2866 ,  C07K16/2896 ,  C07K16/36 ,  C07K16/468 ,  A61K2039/507 ,  C07K2317/14 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/56 ,  C07K2317/94

Abstract: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.

公开(公告)号：US20240343831A1

公开(公告)日：2024-10-17

申请号：US18642721

申请日：2024-04-22

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Alina BAUM ,  Christos KYRATSOUS ,  Lisa PURCELL

IPC: C07K16/40 ,  A61K39/395 ,  A61K45/06 ,  C12N9/50

CPC classification number: C07K16/40 ,  A61K39/3955 ,  A61K45/06 ,  C12N9/50 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/92

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to TMPRSS2 and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections or influenza virus infections).

公开(公告)号：US20240343808A1

公开(公告)日：2024-10-17

申请号：US18392954

申请日：2023-12-21

Applicant: Novartis AG ,  DANA-FARBER CANCER INSTITUTE, INC. ,  PRESIDENT AND FELLOWS OF HARVARD COLLEGE

Inventor： Gordon James Freeman ,  Arlene Helen Sharpe ,  Gerhard Johann Frey ,  Hwai Wen Chang ,  Jennifer Marie Mataraza ,  Glenn Dranoff

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61N5/10 ,  C07K16/30 ,  G01N33/574

CPC classification number: C07K16/2827 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61N5/10 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3069 ,  G01N33/57492 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2333/70532

Abstract: Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.

公开(公告)号：US20240343790A1

公开(公告)日：2024-10-17

申请号：US18627131

申请日：2024-04-04

Applicant: Genzyme Corporation

Inventor： Huawei Qiu ,  Clark Pan ,  Julie Bird

IPC: C07K16/22 ,  A61K39/00 ,  A61K39/395 ,  C07K16/00 ,  C07K16/46 ,  C12N15/11 ,  C12N15/62

CPC classification number: C07K16/22 ,  A61K39/395 ,  A61K39/3955 ,  C07K16/00 ,  C07K16/46 ,  C12N15/11 ,  C12N15/62 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/64 ,  C07K2317/70 ,  C07K2317/72 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/23 ,  C07K2319/73

Abstract: An scFv-Fc dimer binds and neutralizes TGFβ1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGFβ1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.